Fresenius SE & Co KGaA Secures EU Approval for Groundbreaking Biosimilars

Fresenius SE & Co KGaA, a leading global healthcare group, has achieved a major breakthrough with the recent EU approval of two Denosumab biosimilars, Conexxence and Bomyntra. These innovative treatments are poised to make a significant impact on the market, offering patients and healthcare providers a more accessible and affordable solution for various indications, including osteoporosis in postmenopausal women.

This development is expected to have a profoundly positive effect on Fresenius SE & Co KGaA’s business, driving growth and profitability in the years to come. The company’s strong fundamentals, coupled with its solid presence in the healthcare sector, position it well to capitalize on this opportunity.

• Key highlights of the EU approval:
  • Conexxence and Bomyntra are the first Denosumab biosimilars to receive EU approval
  • These treatments are expected to be available for various indications, including osteoporosis in postmenopausal women
  • The approval is a significant milestone for Fresenius SE & Co KGaA, underscoring the company’s commitment to innovation and patient care

The recent EU approval is a testament to Fresenius SE & Co KGaA’s dedication to advancing the field of healthcare. As the company continues to push the boundaries of what is possible, investors and stakeholders can expect to see a sustained commitment to growth and profitability. With a solid track record and a strong presence in the market, Fresenius SE & Co KGaA is well-positioned to capitalize on the opportunities presented by this groundbreaking development.